^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Hensify (crystalline hafnium oxide)

    i
    Other names: JNJ1900, JNJ 1900, JNJ-90301900, NBTXR3, PEP503, PEP-503, NBTXR 3, NBTX 3, NBTXR-3, JNJ-1900
    Associations

    News

    Trials
    Company:
    J&J, LianBio, Nanobiotix
    Drug class:
    Free radical stimulant, Radiosensitiser
    Related drugs:
    Associations

    News

    Trials
    5d
    Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=40, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    Hensify (crystalline hafnium oxide)
    19d
    NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer (clinicaltrials.gov)
    P2, N=14, Terminated, M.D. Anderson Cancer Center | Trial completion date: Sep 2026 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Jan 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Hensify (crystalline hafnium oxide)
    2ms
    LUMIRAY: A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Johnson & Johnson Enterprise Innovation Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Hensify (crystalline hafnium oxide)
    2ms
    NANORAY-312: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (clinicaltrials.gov)
    P3, N=500, Recruiting, Johnson & Johnson Enterprise Innovation Inc. | Trial completion date: Dec 2027 --> Jun 2028
    Trial completion date
    |
    Erbitux (cetuximab) • Hensify (crystalline hafnium oxide)
    3ms
    NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=24 --> 34
    Enrollment closed • Enrollment change
    |
    Hensify (crystalline hafnium oxide)
    3ms
    NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    Hensify (crystalline hafnium oxide)
    3ms
    NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical • Hensify (crystalline hafnium oxide)
    4ms
    Study 1100: NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy (clinicaltrials.gov)
    P1, N=145, Active, not recruiting, Nanobiotix | Recruiting --> Active, not recruiting | Trial completion date: May 2028 --> Aug 2027
    Enrollment closed • Trial completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Hensify (crystalline hafnium oxide)
    4ms
    A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Johnson & Johnson Enterprise Innovation Inc.
    New P1 trial
    |
    Hensify (crystalline hafnium oxide)
    6ms
    NANORAY-312: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (clinicaltrials.gov)
    P3, N=500, Recruiting, Johnson & Johnson Enterprise Innovation Inc. | Trial completion date: Jun 2027 --> Dec 2027
    Trial completion date
    |
    Erbitux (cetuximab) • Hensify (crystalline hafnium oxide)
    8ms
    NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, M.D. Anderson Cancer Center | N=60 --> 14 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Hensify (crystalline hafnium oxide)
    1year
    NANORAY-312: NBTXR3 With or Without Cetuximab in LA-HNSCC (clinicaltrials.gov)
    P3, N=500, Recruiting, Nanobiotix | Trial completion date: Jan 2026 --> Jun 2027 | Trial primary completion date: Jul 2024 --> Jun 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Erbitux (cetuximab) • Hensify (crystalline hafnium oxide)